Nagla Karim, MD

No bio available.

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Janssen
    Date added:
    08/27/2024
    Date updated:
    08/27/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    MERCK
    Date added:
    08/27/2024
    Date updated:
    08/27/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Novocure
    Date added:
    08/27/2024
    Date updated:
    08/27/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Pfizer
    Date added:
    08/27/2024
    Date updated:
    08/27/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    G1 Therapeutics
    Date added:
    08/27/2024
    Date updated:
    08/27/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Immunogen
    Date added:
    08/27/2024
    Date updated:
    08/27/2024

Pages

Return to Sept. 27-28, 2024 - Symposium for Evolving Therapies and Drug Development in Oncology